Presence & RecognitionEvent: September 3, 2026
NeoGenomics Laboratories presented research on AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens at AACR 2026, along with AI applications for automated phenotyping of multiplex immunofluorescence data.
Published
Signal category
Presence & Recognition
Quote
“At AACR 2026, NeoGenomics presented research on AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens, along with AI applications for automated phenotyping of multiplex immunofluorescence data.”
— Halit Kolenovic, MBA|NeoGenomics Laboratories team
Company
NeoGenomics Laboratories
Answers are in our DNA™
- Industry
- Hospitals and Health Care
- Location
- Fort Myers, US
- Company size
- 1,841 employees
Our vision: A world where every cancer treatment decision is as personal as the patient. Our mission: We take cancer personally. We partner with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes -- through a comprehensive oncology portfolio and an unwavering commitment to excellence powered by a team of dedicated experts.
Founded 2002